Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 5/20 | 0.35 |
| ▸ | ADORA2A | P29274 | 5/20 | 0.35 |
| ▸ | ADORA1 | P30542 | 5/20 | 0.35 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.35 |
| ▸ | AKT1 | P31749 | 1/20 | 0.35 |
| ▸ | AKT2 | P31751 | 1/20 | 0.35 |
| ▸ | GABRG2 | P18507 | 12/20 | 0.33 |
| ▸ | GABRB3 | P28472 | 12/20 | 0.33 |
| ▸ | GABRA5 | P31644 | 12/20 | 0.33 |
| ▸ | GABRA1 | P14867 | 11/20 | 0.33 |
| ▸ | GABRA3 | P34903 | 11/20 | 0.33 |
| ▸ | GABRA2 | P47869 | 11/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9909131 | 0.81 | AKT1 (0.33) | ADORA3ADORA2AADORA1ADORA2BAKT1 | |
| SCHEMBL9909143 | 0.78 | MEN1 (0.34) | ADORA3ADORA2AADORA1ADORA2BAKT1 | |
| SCHEMBL9909151 | 0.76 | PDE10A (0.34) | — | |
| SCHEMBL9907121 | 0.64 | — | — | |
| SCHEMBL13746750 | 0.63 | — | — | |
| SCHEMBL1204188 | 0.60 | F2R (0.34) | AKT1AKT2 | |
| SCHEMBL9909155 | 0.59 | CACNA2D1 (0.32) | ADORA3ADORA2AADORA1ADORA2B | |
| SCHEMBL10264202 | 0.55 | LRRK2 (0.33) | — | |
| SCHEMBL30986 | 0.55 | SMN1; SMN2 (0.36) | ADORA1AKT1AKT2 | |
| SCHEMBL26940043 | 0.55 | MEN1 (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2240486-B1 | TRIAZOLIUM SALTS AS PAR1 INHIBITORS, THEIR MANUFACTURE AND THEIR APPLICATION AS MEDICINE | SANOFI SA (FR) | 2015-09-09 | — | — | EP | disclosed |
| US-9079906-B2 | Triazolopyridazines as PAR1 inhibitors, production thereof, and use as medicaments | SANOFI (FR) | 2015-07-14 | — | — | US | disclosed |
| US-8853206-B2 | Triazolium salts as PAR1 inhibitors, production thereof, and use as medicaments | SANOFI (FR) | 2014-10-07 | — | — | US | disclosed |
| US-20120208805-A1 | TRIAZOLIUM SALTS AS PAR1 INHIBITORS, PRODUCTION THEREOF, AND USE AS MEDICAMENTS | SANOFI (FR) | 2012-08-16 | — | — | US | disclosed |
| US-8198272-B2 | Triazolium salts as PAR1 inhibitors, production thereof, and use as medicaments | SANOFI-AVENTIS (FR) | 2012-06-12 | — | — | US | disclosed |
| US-20120010203-A1 | TRIAZOLOPYRIDAZINES AS PAR1 INHIBITORS, PRODUCTION THEREOF, AND USE AS MEDICAMENTS | SANOFI-AVENTIS (FR) | 2012-01-12 | — | — | US | disclosed |
| EP-2240487-B1 | TRIAZOLOPYRIDAZINES AS PAR1 INHIBITORS, PRODUCTION THEREOF, AND USE AS MEDICAMENTS | SANOFI SA (FR) | 2011-12-14 | — | — | EP | disclosed |
| US-8076336-B2 | Triazolopyridazines as PAR1 inhibitors, production thereof, and use as medicaments | SANOFI-AVENTIS (FR) | 2011-12-13 | — | — | US | disclosed |
| US-20110034451-A1 | TRIAZOLOPYRIDAZINES AS PAR1 INHIBITORS, PRODUCTION THEREOF, AND USE AS MEDICAMENTS | SANOFI-AVENTIS (FR) | 2011-02-10 | — | — | US | disclosed |
| US-20110034452-A1 | TRIAZOLIUM SALTS AS PAR1 INHIBITORS, PRODUCTION THEREOF, AND USE AS MEDICAMENTS | SANOFI-AVENTIS (FR) | 2011-02-10 | — | — | US | disclosed |
| WO-2009097970-A1 | TRIAZOLOPYRIDAZINES AS PAR1 INHIBITORS, PRODUCTION THEREOF, AND USE AS MEDICAMENTS | SANOFI-AVENTIS (FR) | 2009-08-13 | — | — | WO | disclosed |
| WO-2009097971-A1 | TRIAZOLIUM SALTS AS PAR1 INHIBITORS, PRODUCTION THEREOF, AND USE AS MEDICAMENTS | SANOFI-AVENTIS (FR) | 2009-08-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110034451-A1 | TRIAZOLOPYRIDAZINES AS PAR1 INHIBITORS, PRODUCTION THEREOF, AND USE AS MEDICAMENTS | F2R, F2RL3, F2RL1 | ADORA3 231/4885ADORA2A 541/4885ADORA1 123/4885 |
| US-20120208805-A1 | TRIAZOLIUM SALTS AS PAR1 INHIBITORS, PRODUCTION THEREOF, AND USE AS MEDICAMENTS | F2R, F2RL3, F2RL1 | ADORA3 123/4885ADORA2A 765/4885ADORA1 51/4885 |
| US-20110034452-A1 | TRIAZOLIUM SALTS AS PAR1 INHIBITORS, PRODUCTION THEREOF, AND USE AS MEDICAMENTS | F2R, F2RL3, F2RL1 | ADORA3 129/4885ADORA2A 782/4885ADORA1 51/4885 |
| US-20120010203-A1 | TRIAZOLOPYRIDAZINES AS PAR1 INHIBITORS, PRODUCTION THEREOF, AND USE AS MEDICAMENTS | F2R, F2RL3, F2RL1 | ADORA3 231/4885ADORA2A 541/4885ADORA1 123/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.